東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

TRAIL, Fas Ligand, TNF and TLR3 in c...

Micheau, Olivier.

Linked to FindBook

Google Book

Amazon

博客來

TRAIL, Fas Ligand, TNF and TLR3 in cancer

Record Type:	Electronic resources : Monograph/item
Title/Author:	TRAIL, Fas Ligand, TNF and TLR3 in cancer/ edited by Olivier Micheau.
other author:	Micheau, Olivier.
Published:	Cham :Springer International Publishing : : 2017.,
Description:	xiii, 317 p. :ill., digital ;24 cm.
[NT 15003449]:	Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer -- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer -- IAPs and Resistance to Death Receptors in Cancer -- Bcl-2 Proteins and TRAIL Resistance in Melanoma -- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4 -- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy -- Atypical Immune Functions of CD95/CD95L -- TLR3 is a Death Receptor Target in Cancer Therapy -- Fas/CD95, Lipid Rafts and Cancer -- Role of Sphingolipids in Death Receptor Signalling -- Post-Translational Modifications and Death Receptor Signalling -- System Modeling of Receptor-Induced Apoptosis.
Contained By:	Springer eBooks
Subject:	Cancer - Treatment. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-56805-8
ISBN:	9783319568058

TRAIL, Fas Ligand, TNF and TLR3 in cancer
TRAIL, Fas Ligand, TNF and TLR3 in cancer[electronic resource] /edited by Olivier Micheau. - Cham :Springer International Publishing :2017. - xiii, 317 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.122196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.12..

Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer -- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer -- IAPs and Resistance to Death Receptors in Cancer -- Bcl-2 Proteins and TRAIL Resistance in Melanoma -- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4 -- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy -- Atypical Immune Functions of CD95/CD95L -- TLR3 is a Death Receptor Target in Cancer Therapy -- Fas/CD95, Lipid Rafts and Cancer -- Role of Sphingolipids in Death Receptor Signalling -- Post-Translational Modifications and Death Receptor Signalling -- System Modeling of Receptor-Induced Apoptosis.

This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.

ISBN: 9783319568058

Standard No.: 10.1007/978-3-319-56805-8doiSubjects--Topical Terms:

618125
Cancer
--Treatment.

LC Class. No.: RC270.8

Dewey Class. No.: 616.99406

TRAIL, Fas Ligand, TNF and TLR3 in cancer
LDR:02301nmm a2200325 a 4500 001 2105408
003 DE-He213
005 20170703154220.0
006 m d
007 cr nn 008maaau
008 180417s2017 gw s 0 eng d
020 $a 9783319568058 $q (electronic bk.)
020 $a 9783319568041 $q (paper)
024 7 $a 10.1007/978-3-319-56805-8 $2 doi
035 $a 978-3-319-56805-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RC270.8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99406 $2 23
090 $a RC270.8 $b .T766 2017
245 0 0 $a TRAIL, Fas Ligand, TNF and TLR3 in cancer $h [electronic resource] / $c edited by Olivier Micheau.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a xiii, 317 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.12
505 0 $a Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer -- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer -- IAPs and Resistance to Death Receptors in Cancer -- Bcl-2 Proteins and TRAIL Resistance in Melanoma -- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4 -- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy -- Atypical Immune Functions of CD95/CD95L -- TLR3 is a Death Receptor Target in Cancer Therapy -- Fas/CD95, Lipid Rafts and Cancer -- Role of Sphingolipids in Death Receptor Signalling -- Post-Translational Modifications and Death Receptor Signalling -- System Modeling of Receptor-Induced Apoptosis.
520 $a This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.
650 0 $a Cancer $x Treatment. $3 618125
650 0 $a Apoptosis. $3 600650
650 0 $a Cell receptors. $3 604615
650 0 $a Tumor necrosis factor $x Receptors. $3 3250226
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Cancer Research. $3 891172
700 1 $a Micheau, Olivier. $3 3250224
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.12. $3 3250225
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-56805-8
950 $a Biomedical and Life Sciences (Springer-11642)